Phase 1, single-center, open-label, non-randomized, sequential single dose 4-period study in
12 healthy subjects to assess the pharmacokinetics of ALZ-801, tramiprosate and the primary
metabolite of tramiprosate, NRM5074, from prototype drug product formulations of ALZ-801, and
to assess effect of food on the bioavailability of ALZ-801 and tramiprosate of the prototype
tablet formulation.